Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer
AuthorsFischer, Stefanie C
AffiliationManchester Cancer Research Centre, Division of Cancer Sciences, University of Manchester, 555 Wilmslow Road, Manchester M204GJ, United Kingdom
MetadataShow full item record
AbstractIntroduction: Loss of skeletal muscle (SM) and gain of subcutaneous fat (SCF) are known side-effects of androgen-deprivation in treatment of prostate cancer. Scarce data is available concerning the effects of abiraterone/pred (ABI) on body composition and no published data regarding enzalutamide (ENZA). Our objective was to analyse the effects of ENZA on SM/SCF and to compare the results with ABI in patients with metastatic castration-resistant prostate-cancer (mCRPC). Patients and methods: 54 patients starting ABI (n = 17) or ENZA (n = 37) at a single-centre between 2012 and 2018 were retrospectively identified. SM and SCF were assessed using CT-scans at baseline and after a median of 10.8 months on treatment. A deep learning image-segmentation software was used to quantify SM and SCF. In a subgroup of patients receiving ENZA within a trial, we investigated change of SM using serial timepoints. Results: Median time of treatment with ABI/ENZA was 14.6 months. A significant loss of SM compared to baseline was observed for ENZA (mean loss 5.2%, p<0.0001) and ABI (mean loss 3.0%, p = 0.02). SCF was not significantly altered. The effects of both drugs did not differ significantly. Loss of SM occurred early on during treatment with ENZA. Conclusion: Treatment with ENZA seems to lead to a loss of SM which is comparable to that of ABI. Further evaluation in larger patient-cohorts is warranted. In routine care, counselling of patients about side effects of ABI/ENZA should include discussions about SM loss.
CitationFischer S, Clements S, McWilliam A, Green A, Descamps T, Oing C, et al. Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer. Cancer Treat Res Commun. 2020;25:100256.
JournalCancer Treatment and Research Communications
- Comparison of Oncologic Outcomes Between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
- Authors: Chung DY, Kang DH, Kim JW, Kim DK, Lee JY, Hong CH, Cho KS
- Issue date: 2019 Dec 18
- Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.
- Authors: Lu C, Terbuch A, Dolling D, Yu J, Wang H, Chen Y, Fountain J, Bertan C, Sharp A, Carreira S, Isaacs WB, Antonarakis ES, De Bono JS, Luo J
- Issue date: 2020 Sep
- Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression.
- Authors: Becker DJ, Iyengar AD, Punekar SR, Ng J, Zaman A, Loeb S, Becker KD, Makarov D
- Issue date: 2019 May
- The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy.
- Authors: Szarvas T, Csizmarik A, Váradi M, Fazekas T, Hüttl A, Nyirády P, Hadaschik B, Grünwald V, Tschirdewahn S, Shariat SF, Sevcenco S, Maj-Hes A, Kramer G
- Issue date: 2021 May
- Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.
- Authors: Matsubara N, Yamada Y, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S, Otsuka M, Fukasawa S
- Issue date: 2018 Apr